GENE EXPRESSION MARKERS OF ONCOLYTIC VIRUS SENSITIVITY

• US 20120004119A1
• Filed: 06/29/2011
• Published: 01/05/2012
• Est. Priority Date: 06/30/2010
• Status: Abandoned Application

• Current Assignee: Eden Therapeutics, Inc.
• Original Assignee: Eden Therapeutics, Inc.
• Inventors: Lenburg, Marc, Chin, Lynda
• Application Number:
  US13/172,577
• Publication Number:
  US 20120004119A1
• Time in Patent Office: Days
• US Class Current: 506/7
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 2333/125 Newcastle disease virus
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

A method of predicting an efficacy of an oncolytic virus treatment for a tumor comprises calculating a single-gene predictor score for each of a plurality of genes; calculating a predictor score from the sum of the single-gene predictor scores for the plurality of genes; and predicting, if the predictor score is greater than a predictor score threshold, that the treatment would have efficacy, and if the predictor score is less than a predictor score threshold, that the treatment would lack efficacy. Also, methods of predicting an efficacy of a treatment for a tumor comprise identifying the type and subtype of the tumor, wherein the efficacy of the treatment for the type and subtype of the tumor is known.

Claims

1. A method, comprising:

determining an expression level for each of a plurality of genes in a tumor sample obtained from a patient;

calculating a total predictor score based on the expression levels for each of the plurality of genes; and

predicting, if the total predictor score satisfies a first predictor score threshold, that an oncolytic virus treatment for the tumor would have efficacy, and if the total predictor score satisfies a second predictor score threshold, that the oncolytic virus treatment for the tumor would lack efficacy.

2. The method of claim 1, wherein the total predictor score is calculated from a single-gene predictor score for each of the plurality of genes, wherein each single-gene predictor score is calculated from a multiplier for the gene times (the expression level in the tumor sample minus a threshold value for the gene) divided by a weight for the gene,

wherein:

the threshold value for each gene is equal to a measure of central tendency between reference expression levels of the gene in a first plurality of tumor lines or tumor tissues known to be sensitive to the oncolytic virus treatment and a second plurality of tumor lines or tumor tissues known to be resistant to the oncolytic virus treatment;

the weight for each gene is equal to a measure of the variability of reference expression levels within the first plurality of tumor lines or tumor tissues and within the second plurality of tumor lines or tumor tissues; and

the multiplier for each gene is equal to 1, if a measure of central tendency of the reference expression levels of the gene in the first plurality of tumor lines or tumor tissues is greater than the threshold value, or −

1, if a measure of central tendency of the reference expression levels of the gene in the second plurality of tumor lines or tumor tissues is greater than the threshold value.

3. The method of claim 1, wherein the oncolytic virus is an RNA oncolytic virus.

4. The method of claim 3, wherein the RNA oncolytic virus is a paramyxovirus.

5. The method of claim 4, wherein the paramyxovirus is a Newcastle Disease Virus (NDV).

6. The method of claim 1, wherein each of the first plurality of tumor lines or tumor tissues and the second plurality of tumor lines or tumor tissues are of the same tumor type as the tumor.

7. The method of claim 1, wherein the tumor is a tumor of the central nervous system, skin, bladder, breast, esophagus, kidney, liver, lung, ovary, pancreas, stomach, uterus, cervix, testicle, or colon, or a metastasis thereof.

8. The method of claim 1, wherein the plurality of genes comprises at least two of:

ABI3BP, AGXT2L2, AKR1C1, ANKRD5, ANLN, ANO10, ANTXR2, ANXA1, ARC, ARL2, ATF7IP, ATP6V0A2, ATRIP, AUTS2, AXGT2L2, BAD, BCL9L, BLM, BR13, C10orf11, C14orf106, C14orf45, C15orf5, C17orf76, C1orf115, C1orf31, C20orf134, C20orf88, C21orf91, C2orf88, C4orf32, C6orf226, C7orf31, C7org106, CA14, CALCOCO2, CBX5, CBX6, CCDC109B, CCDC30, CCDC45, CD44, CD83, CDK5R1, CEP152, CHD1, CHKA, CPT1C, CPVL, CTSA, CYP4V2, DAPK1, DCDC2, DDX60L, DEPDC7, DHX33, DNM1L, DUS1L, EHD2, ETV2, F2R, F8, FAM129B, FAM174B, FAM178A, FIBP, FKBP10, FLJ10213, FSCN1, FSTL5, FTO, GALNT3, GARNL4, GMPR, GNA12, GPR137B, GPR143, GPX4, GPX7, hCG 20036, HHAT, HIST1H2BH, HK1, HMGA2, HOOK1, HOXA10, HOXA13, HOXA3, HOXA5, HOXA6, HOXB7, HOXB9, HOXB9K, HPS4, ICAM3, IGFBP3, IKAA1324L, IL12RB2, INTS2, ITGA5, ITGA7, ITM2C, ITPKB, IVNS1ABP, KCNA4, KCNK1, KCNN4, KCTD17, KIAA0355, KIAA0652, KIAA1324, KIAA1598, KIF23, LINS1, LOC152217, LOC202781, LOC401068, LPPR2, LRRC29, LVN, MAGEH1, MAN1B1, MAP4K3, MAPKAPK3, MBL1P1, MECOM, MED16, MEPCE, MESDC1, MFAP2, MGAT4A, MICAL3, MOSC2, MOSPD1, MRS2, MVP, MYADM, MYOM2, NCALD, NCOA6, NDRG1, NDUFV1, NEIL2, NELL1, NEO1, NFASC, NFIC, NINL, NME5, NNMT, NOL3, NR1D1, NRP1, NUDT22, OSCP1, OTUB1, PAEP, PCDH18, PCDH96, PCDHB11, PCDHB16, PCDHB2, PCDHB6, PCDHB8, PCF11, PDCD2, PDCHB11, PDE8A, PFTK1, PGBD5, PGLYRP2, PHLPP2, PHPT1, PHYH, PITPNM1, PLAG1, PLCL2, PNLPA6, POGK, POLD4, POLDIP2, PPAP2C, PPM1H, PPP2R1A, PRRX1, PTMS, PTRF, PUM2, PUS3, RAB11FIP4, RAB15, RAB17, RAB1B, RABG1G, RASSF8, RBMS3, RC3H1, RCOR3, RGS10, RGS20, RNF187, ROM1, RRAS, RSPO3, RTN4, SB3BGRL3, SEMA6A, SEPT3, SERGEF, SERPINH1, SFRS15, SH3BGRL3, SH3YL1, SKA2, SLC16A6, SLC17A5, SLC27A3, SLC2A3P1, SLC44A3, SMOX, SNAPC2, SNX21, SORBS1, SOX8, SP4, SPAG4, SPAG9, ST6GALNAC, SUMF2, SYCP2, TBRG1, THBS3, THYN1, TIK2, TK1, TK2, TM4SF18, TMEM170B, TMEM60, TNFRSF1A, TNKS1BP1, TOB1, TOM1, TRPC3, TRPS1, TSC22D3, TTYH2, TUG1, UBASH3B, UBXN6, WNT5A, WT1, ZBTB41, ZBTB47, ZEB1, ZFP36L1, ZMYM2, ZNF138, ZNF175, ZNF195, ZNF280C, ZNF462, ZNF561, or ZXDB.

9. The method of claim 8, wherein the plurality of genes comprises the genes listed in Table 1, the genes listed in Table 2, the genes listed in Table 3, the genes listed in Table 4, the genes listed in Table 5, the genes listed in Table 6, the genes listed in Table 7, the genes listed in Table 8, the genes listed in Table 9, the genes listed in Table 10, the genes listed in Table 11, the genes listed in Table 12, the genes listed in Table 13, the genes listed in Table 14, the genes listed in Table 15, or two or more thereof.

10. A kit for predicting an efficacy of an oncolytic virus treatment for a tumor, the kit comprising:

reagents for measuring an expression level for each of a plurality of genes in a tumor sample obtained from a patient, wherein the plurality of genes comprises at least two of;

ABI3BP, AGXT2L2, AKR1C1, ANKRD5, ANLN, ANO10, ANTXR2, ANXA1, ARC, ARL2, ATF7IP, ATP6V0A2, ATRIP, AUTS2, AXGT2L2, BAD, BCL9L, BLM, BR13, C10orf11, C14orf106, C14orf45, C15orf5, C17orf76, C1orf115, C1orf31, C20orf134, C20orf88, C21orf91, C2orf88, C4orf32, C6orf226, C7orf31, C7org106, CA14, CALCOCO2, CBX5, CBX6, CCDC109B, CCDC30, CCDC45, CD44, CD83, CDK5R1, CEP152, CHD1, CHKA, CPT1C, CPVL, CTSA, CYP4V2, DAPK1, DCDC2, DDX60L, DEPDC7, DHX33, DNM1L, DUS1L, EHD2, ETV2, F2R, F8, FAM129B, FAM174B, FAM178A, FIBP, FKBP10, FLJ10213, FSCN1, FSTL5, FTO, GALNT3, GARNL4, GMPR, GNA12, GPR137B, GPR143, GPX4, GPX7, hCG 20036, HHAT, HIST1H2BH, HK1, HMGA2, HOOK1, HOXA10, HOXA13, HOXA3, HOXA5, HOXA6, HOXB7, HOXB9, HOXB9K, HPS4, ICAM3, IGFBP3, IKAA1324L, IL12RB2, INTS2, ITGA5, ITGA7, ITM2C, ITPKB, IVNS1ABP, KCNA4, KCNK1, KCNN4, KCTD17, KIAA0355, KIAA0652, KIAA1324, KIAA1598, KIF23, LINS1, LOC152217, LOC202781, LOC401068, LPPR2, LRRC29, LVN, MAGEH1, MAN1B1, MAP4K3, MAPKAPK3, MBL1P1, MECOM, MED16, MEPCE, MESDC1, MFAP2, MGAT4A, MICAL3, MOSC2, MOSPD1, MRS2, MVP, MYADM, MYOM2, NCALD, NCOA6, NDRG1, NDUFV1, NEIL2, NELL1, NEO1, NFASC, NFIC, NINL, NME5, NNMT, NOL3, NR1D1, NRP1, NUDT22, OSCP1, OTUB1, PAEP, PCDH18, PCDH96, PCDHB11, PCDHB16, PCDHB2, PCDHB6, PCDHB8, PCF11, PDCD2, PDCHB11, PDE8A, PFTK1, PGBD5, PGLYRP2, PHLPP2, PHPT1, PHYH, PITPNM1, PLAG1, PLCL2, PNLPA6, POGK, POLD4, POLDIP2, PPAP2C, PPM1H, PPP2R1A, PRRX1, PTMS, PTRF, PUM2, PUS3, RAB11FIP4, RAB15, RAB17, RAB1B, RABG1G, RASSF8, RBMS3, RC3H1, RCOR3, RGS10, RGS20, RNF187, ROM1, RRAS, RSPO3, RTN4, SB3BGRL3, SEMA6A, SEPT3, SERGEF, SERPINH1, SFRS15, SH3BGRL3, SH3YL1, SKA2, SLC16A6, SLC17A5, SLC27A3, SLC2A3P1, SLC44A3, SMOX, SNAPC2, SNX21, SORBS1, SOX8, SP4, SPAG4, SPAG9, ST6GALNAC, SUMF2, SYCP2, TBRG1, THBS3, THYN1, TIK2, TK1, TK2, TM4SF18, TMEM170B, TMEM60, TNFRSF1A, TNKS1BP1, TOB1, TOM1, TRPC3, TRPS1, TSC22D3, TTYH2, TUG1, UBASH3B, UBXN6, WNT5A, WT1, ZBTB41, ZBTB47, ZEB1, ZFP36L1, ZMYM2, ZNF138, ZNF175, ZNF195, ZNF280C, ZNF462, ZNF561, or ZXDB.

11. The kit of claim 10, wherein the plurality of genes comprises the genes listed in Table 1, the genes listed in Table 2, the genes listed in Table 3, the genes listed in Table 4, the genes listed in Table 5, the genes listed in Table 6, the genes listed in Table 7, the genes listed in Table 8, the genes listed in Table 9, the genes listed in Table 10, the genes listed in Table 11, the genes listed in Table 12, the genes listed in Table 13, the genes listed in Table 14, the genes listed in Table 15, or two or more thereof.

12. The kit of claim 10, wherein the tumor is a tumor of the central nervous system, skin, bladder, breast, esophagus, kidney, liver, lung, ovary, pancreas, stomach, uterus, cervix, testicle, or colon, or a metastasis thereof.

13. The kit of claim 10, further comprising instructions for performing a method comprising:

determining an expression level for each of the plurality of genes;

calculating a total predictor score based on the expression levels for each of the plurality of genes; and

predicting, if the total predictor score satisfies a first predictor score threshold, that an oncolytic virus treatment for the tumor would have efficacy, and if the total predictor score satisfies a second predictor score threshold, that the oncolytic virus treatment for the tumor would lack efficacy.

14. A method, comprising:

determining an expression level for each of a plurality of genes in a tumor sample by at least one of northern blotting, in situ hybridization, RNAse protection assay, reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR, use of an antibody to DNA duplexes, use of an antibody to RNA duplexes, use of an antibody to DNA-RNA hybrid duplexes, use of an antibody to DNA-protein duplexes, Serial Analysis of Gene Expression (SAGE), gene expression analysis by massively parallel signature sequencing (MPSS), a microarray, southern blotting, western blotting, ELISA-like assays, quantum-dot gene expression analysis, or direct digital detection for gene expression analysis,

wherein the plurality of genes comprises at least two of;

ABI3BP, AGXT2L2, AKR1C1, ANKRD5, ANLN, ANO10, ANTXR2, ANXA1, ARC, ARL2, ATF7IP, ATP6V0A2, ATRIP, AUTS2, AXGT2L2, BAD, BCL9L, BLM, BR13, C10orf11, C14orf106, C14orf45, C15orf5, C17orf76, C1orf115, C1orf31, C20orf134, C20orf88, C21orf91, C2orf88, C4orf32, C6orf226, C7orf31, C7org106, CA14, CALCOCO2, CBX5, CBX6, CCDC109B, CCDC30, CCDC45, CD44, CD83, CDK5R1, CEP152, CHD1, CHKA, CPT1C, CPVL, CTSA, CYP4V2, DAPK1, DCDC2, DDX60L, DEPDC7, DHX33, DNM1L, DUS1L, EHD2, ETV2, F2R, F8, FAM129B, FAM174B, FAM178A, FIBP, FKBP10, FLJ10213, FSCN1, FSTL5, FTO, GALNT3, GARNL4, GMPR, GNA12, GPR137B, GPR143, GPX4, GPX7, hCG 20036, HHAT, HIST1H2BH, HK1, HMGA2, HOOK1, HOXA10, HOXA13, HOXA3, HOXA5, HOXA6, HOXB7, HOXB9, HOXB9K, HPS4, ICAM3, IGFBP3, IKAA1324L, IL12RB2, INTS2, ITGA5, ITGA7, ITM2C, ITPKB, IVNS1ABP, KCNA4, KCNK1, KCNN4, KCTD17, KIAA0355, KIAA0652, KIAA1324, KIAA1598, KIF23, LINS1, LOC152217, LOC202781, LOC401068, LPPR2, LRRC29, LVN, MAGEH1, MAN1B1, MAP4K3, MAPKAPK3, MBL1P1, MECOM, MED16, MEPCE, MESDC1, MFAP2, MGAT4A, MICAL3, MOSC2, MOSPD1, MRS2, MVP, MYADM, MYOM2, NCALD, NCOA6, NDRG1, NDUFV1, NEIL2, NELL1, NEO1, NFASC, NFIC, NINL, NME5, NNMT, NOL3, NR1D1, NRP1, NUDT22, OSCP1, OTUB1, PAEP, PCDH18, PCDH96, PCDHB11, PCDHB16, PCDHB2, PCDHB6, PCDHB8, PCF11, PDCD2, PDCHB11, PDE8A, PFTK1, PGBD5, PGLYRP2, PHLPP2, PHPT1, PHYH, PITPNM1, PLAG1, PLCL2, PNLPA6, POGK, POLD4, POLDIP2, PPAP2C, PPM1H, PPP2R1A, PRRX1, PTMS, PTRF, PUM2, PUS3, RAB11FIP4, RAB15, RAB17, RAB1B, RABG1G, RASSF8, RBMS3, RC3H1, RCOR3, RGS10, RGS20, RNF187, ROM1, RRAS, RSPO3, RTN4, SB3BGRL3, SEMA6A, SEPT3, SERGEF, SERPINH1, SFRS15, SH3BGRL3, SH3YL1, SKA2, SLC16A6, SLC17A5, SLC27A3, SLC2A3P1, SLC44A3, SMOX, SNAPC2, SNX21, SORBS1, SOX8, SP4, SPAG4, SPAG9, ST6GALNAC, SUMF2, SYCP2, TBRG1, THBS3, THYN1, TIK2, TK1, TK2, TM4SF18, TMEM170B, TMEM60, TNFRSF1A, TNKS1BP1, TOB1, TOM1, TRPC3, TRPS1, TSC22D3, TTYH2, TUG1, UBASH3B, UBXN6, WNT5A, WT1, ZBTB41, ZBTB47, ZEB1, ZFP36L1, ZMYM2, ZNF138, ZNF175, ZNF195, ZNF280C, ZNF462, ZNF561, or ZXDB.

15. The method of claim 14, wherein the plurality of genes comprises the genes listed in Table 1, the genes listed in Table 2, the genes listed in Table 3, the genes listed in Table 4, the genes listed in Table 5, the genes listed in Table 6, the genes listed in Table 7, the genes listed in Table 8, the genes listed in Table 9, the genes listed in Table 10, the genes listed in Table 11, the genes listed in Table 12, the genes listed in Table 13, the genes listed in Table 14, the genes listed in Table 15, or two or more thereof.

16. The method of claim 14, wherein the tumor is a tumor of the central nervous system, skin, bladder, breast, esophagus, kidney, liver, lung, ovary, pancreas, stomach, uterus, cervix, testicle, or colon, or a metastasis thereof.